Standout Papers

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients wit... 2018 2026 2020 2023 264
  1. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia (2018)
    Piers Blombery, Mary Ann Anderson et al. Cancer Discovery

Immediate Impact

1 from Science/Nature 67 standout
Sub-graph 1 of 23

Citing Papers

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
The hallmarks of cancer immune evasion
2024 Standout
2 intermediate papers

Works of Thomas E. Lew being referenced

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
2020
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
2018 Standout

Author Peers

Author Last Decade Papers Cites
Thomas E. Lew 554 414 123 211 32 846
E. Januszewicz 456 398 64 127 41 940
G. Laurent 218 216 72 206 30 743
W.Y. Au 158 152 51 174 37 694
Gaetano Vitelli 287 156 39 298 28 654
Sharon Jackson 191 351 53 136 29 794
Deborah Yallop 417 198 22 217 35 757
Jennifer Dunlap 223 167 117 356 36 934
Ozren Jakšić 395 226 33 180 47 831
Elizabeth Bilotti 573 451 57 231 29 814
L. Austin Doyle 145 242 197 329 33 905

All Works

Loading papers...

Rankless by CCL
2026